BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atezolizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Atezolizumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04808245-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT04808245)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A MultIceNTER Phase I Peptide V
 aCcine Trial for the Treatment of H3-Mutated Gliomas\nEstimated primary co
 mpletion: November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04808245
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05168618-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05168618)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Cabozantinib and Atezolizumab f
 or the Treatment of Metastatic Castration-Resistant Prostate Cancer\nEstim
 ated primary completion: November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05168618
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04958811-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04958811)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 ragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advance
 d Non-squamous NSCLC\nEstimated primary completion: November 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04958811
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02862275-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261121
DTEND;VALUE=DATE:20261122
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT02862275)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Atezolizumab in Treating Patien
 ts With Cancer Following Adoptive Cell Transfer\nEstimated primary complet
 ion: 21 November 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT02862275
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538128-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT07538128)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Evaluating Safety\, Tolerabilit
 y\, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination Wit
 h Atezolizumab for Recurrent Glioblastoma\nEstimated primary completion: 2
 7 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atez
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07538128
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Multiple Therapies in Biomarker-selected Participants With Resect
 able Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03148418-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03148418)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Participants Previou
 sly Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Ate
 zolizumab Study (IMbrella A)\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03148418
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691817-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04691817)
DESCRIPTION:Atezolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic
  Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhib
 itor-Based Therapy\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04691817
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05000294-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05000294)
DESCRIPTION:Atezolizumab\, phase 1/2\, Bladder Cancer.\nStudy: Atezolizumab
  Plus Tivozanib in Immunologically Cold Tumor Types\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05000294
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02989584-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT02989584)
DESCRIPTION:Atezolizumab\, phase 1/2\, Bladder Cancer.\nStudy: A Phase II S
 tudy of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Su
 rgery to Remove the Bladder Cancer\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02989
 584
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03125928-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03125928)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Clinical Trial of Atezolizumab 
 With Paclitaxel\, Trastuzumab\, and Pertuzumab in Patients With Metastatic
  HER-2 Positive Breast Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03125928
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786692-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03786692)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizu
 mab in Stage IV NSCLC\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03786692
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03915678-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03915678)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03915678
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192185-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07192185)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Syst
 emic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients
  With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab\nEst
 imated primary completion: 1 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07192185
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05825625-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05825625)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05825625
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05300282-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05300282)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Study of Atezolizumab Plus BE
 GEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients\nEstimat
 ed primary completion: 15 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05300282
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06690840-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06690840)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab and Chemotherapy T
 reatment as T-cell Activators in Metastatic Triple Negative Breast Cancer 
 Patients\nEstimated primary completion: 15 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06690840
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771518-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06771518)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Associ
 ation of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy T
 reatment With Atezolizumab\nEstimated primary completion: 15 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06771518
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03595592-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03595592)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: Neoadjuvant Treatment of HER2 P
 ositive Early High-risk and Locally Advanced Breast Cancer\nEstimated prim
 ary completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03595592
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254911-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06254911)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Pre-operative Atezolizumab in P
 atients With Resectable\, Human Papillomavirus Related Oropharyngeal Carci
 noma\nEstimated primary completion: 16 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06254911
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT04185883)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Sotorasib Activity in Subjects 
 With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)\nEsti
 mated primary completion: 17 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03474094-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03474094)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Clinical and Biological Activit
 y of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcom
 as Patients to be Treated With Radiotherapy\nEstimated primary completion:
  30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/at
 ezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03474094
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04434040-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04434040)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab + Sacituzumab Govi
 tecan to Prevent Recurrence in TNBC (ASPRIA)\nEstimated primary completion
 : 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 tezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04434040
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488522-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05488522)
DESCRIPTION:Atezolizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: SBRT
  With Atezo/Bev for HCC\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05488522
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05340309-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05340309)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Su
 bcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05340309
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03784326-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03784326)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Phase I/II Study of Perioperati
 ve Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esopha
 geal and Gastroesophageal Adenocarcinoma\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezo
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03784326
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807632-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06807632)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: A Stud
 y of Valemetostat in Combination With Atezolizumab in People With Lung Can
 cer\nEstimated primary completion: January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06807632
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04796012-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04796012)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: VITAS: Atezolizumab in Combin
 ation With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04796012
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04467723-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04467723)
DESCRIPTION:Atezolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCL
 C\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04467723
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Di
 clofenac for the Treatment of Patients With Metastatic Non-small Cell Lung
  Cancer on Single Agent Immunotherapy\nEstimated primary completion: 1 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6731270
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276100-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07276100)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Fecal Microbiota Transplantatio
 n to RESCUE Patients With Unresectable Hcc Progressors to First Line Thera
 py With AtezolizUmaB and Bevacizumab\nEstimated primary completion: 1 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 276100
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560972-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270127
DTEND;VALUE=DATE:20270128
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT04560972)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: LB-100
 \, Carboplatin\, Etoposide\, and Atezolizumab for the Treatment of Untreat
 ed Extensive-Stage Small Cell Lung Cancer\nEstimated primary completion: 2
 7 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezo
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04560972
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096715-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05096715)
DESCRIPTION:Atezolizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab+Bevacizumab+SBRT in Unresectable HCC\nEstimated primary completio
 n: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 tezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05096715
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06066138-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06066138)
DESCRIPTION:Atezolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing\nEstimated 
 primary completion: 31 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06066138
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04186013-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04186013)
DESCRIPTION:Atezolizumab\, phase 2\, Bladder Cancer.\nStudy: Efficacy of At
 ezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive B
 ladder cáncer\nEstimated primary completion: February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04186013
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05798663-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05798663)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unr
 esectable Stage III NSCLC\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05798663
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05377034-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05377034)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Mult
 inational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resi
 n Microspheres) Followed by Atezolizumab Plus Bevacizumab\, vs SIRT (SIRT-
 Y90) Followed by Placebo in Locally Advanced HCC Patients\nEstimated prima
 ry completion: 15 February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05377034
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02846623-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT02846623)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab\, Obinutuzumab\, a
 nd Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia\, Sma
 ll Lymphocytic Lymphoma\, or Relapsed or Refractory Richter Syndrome\nEsti
 mated primary completion: 28 February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT02846623
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246668-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07246668)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Ph
 ase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Ca
 rbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therap
 y in Patients With Advanced Hepatocellular Carcinoma\nEstimated primary co
 mpletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07246668
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05516628-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05516628)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Deep
 \, Multi-omics Phenotyping to Predict Response\, Resistance and Recurrence
  to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carc
 inoma\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05516628
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Atezolizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study o
 f a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpo
 int Blockade for Patients With Metastatic Colorectal Cancer\nEstimated pri
 mary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05141721
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Short-term Fasting Prior to PD-
 1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06077500-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06077500)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: DAREON
 ᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Additio
 n to Standard of Care Are Tolerated by People With Advanced Small Cell Lun
 g Cancer\nEstimated primary completion: 31 March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06077500
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830694-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06830694)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Clinic
 al Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) Wi
 th Etoposide\, Carboplatin and Atezolizumab in Transformed Small Cell Lung
  Cancer Patients From Adenocarcinoma After EGFR TKI Treatment\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06830694
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04873362-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04873362)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study Evaluating the Efficacy
  and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine 
 for Participants With HER2-Positive Breast Cancer at High Risk of Recurren
 ce Following Preoperative Therapy\nEstimated primary completion: 31 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048733
 62
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118724-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05118724)
DESCRIPTION:Atezolizumab\, phase 2\, Colorectal Cancer.\nStudy: Atezolizuma
 b in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal
  Cancer Ineligible for Oxaliplatin\nEstimated primary completion: April 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05118724
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434234-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05434234)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study of YL201 in Patients 
 With Advanced Solid Tumors\nEstimated primary completion: 6 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05434234
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06595108-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Atezolizumab: Phase na readout est. (NCT06595108)
DESCRIPTION:Atezolizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Ate
 zolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced
  Hepatocellular Carcinoma\nEstimated primary completion: 25 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06595108
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03821246-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03821246)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Neoadjuvant Atezolizumab-Based 
 Combination Therapy in Men With Localized Prostate Cancer Prior to Radical
  Prostatectomy\nEstimated primary completion: 30 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03821246
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185505-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Atezolizumab: Phase 4 readout est. (NCT05185505)
DESCRIPTION:Atezolizumab\, phase 4\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepat
 ocellular Carcinoma Beyond Milan Criteria\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05185505
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03896074-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03896074)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Pat
 ients (BEAT)\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03896074
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767075-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03767075)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Modular Multi-Basket Trial to
  Improve Personalized Medicine in Cancer Patients (Basket of Baskets)\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03767075
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05333458-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05333458)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Testing Atezolizumab With Selin
 exor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma\, AXIOM Tr
 ial\nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05333458
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537310-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06537310)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Dose-escalation Study of RO75
 67132 as Single Agent and in Combination With Atezolizumab in Participants
  With Advanced Solid Tumors\nEstimated primary completion: 12 May 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06537310
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440708-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05440708)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A 
 Study of TTI-101 as Monotherapy and in Combination in Participants With Lo
 cally Advanced or Metastatic\, and Unresectable Hepatocellular Carcinoma\n
 Estimated primary completion: 25 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05440708
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179069-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06179069)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: A Stud
 y of ZL-1310 in Subjects With Small Cell Lung Cancer\nEstimated primary co
 mpletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06179069
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03421288-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03421288)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Study of Atezolizumab + FLOT vs
 . FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness\nEstim
 ated primary completion: 31 May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03421288
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04721132-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04721132)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab Before Surgery for the Treatment of Resectable Li
 ver Cancer\nEstimated primary completion: 31 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04721132
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498896-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05498896)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Investigate the Contribution of
  Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC\nEstima
 ted primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05498896
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492954-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06492954)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Atezolizumab in Combination Wit
 h Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Oste
 osarcoma\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06492954
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812366-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04812366)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Genomic Biomarker-Selected Umbr
 ella Neoadjuvant Study for High Risk Localized Prostate Cancer\nEstimated 
 primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04812366
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04310020-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04310020)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-s
 mall Cell Lung Cancer Patients\nEstimated primary completion: 1 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04310020
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02997228-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT02997228)
DESCRIPTION:Atezolizumab\, phase 3\, Colorectal Cancer.\nStudy: Testing the
  Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alon
 e for Metastatic Colon or Rectal Cancer\, the COMMIT Study\nEstimated prim
 ary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT02997228
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03321643-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT03321643)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Testing the Addition of an Immu
 notherapy Agent\, Atezolizumab\, When Given With the Usual Chemo-Immunothe
 rapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Rel
 apsed/Refractory (That Has Come Back or Not Responded to Treatment) Transf
 ormed Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 30 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03321
 643
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06110572-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06110572)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Phase I/II Trial in ES-SCLC t
 o Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irrad
 iation\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06110572
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02935361-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT02935361)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Guadecitabine and Atezolizuma
 b in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic M
 yelomonocytic Leukemia That Is Refractory or Relapsed\nEstimated primary c
 ompletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02935361
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT00781612)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Safety Extension Study of Tra
 stuzumab Emtansine in Participants Previously Treated With Trastuzumab Emt
 ansine Alone or in Combination With Other Anti-Cancer Therapy in One of th
 e Parent Studies\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT00781612
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03237780-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03237780)
DESCRIPTION:Atezolizumab\, phase 2\, Bladder Cancer.\nStudy: Atezolizumab W
 ith or Without Eribulin Mesylate in Treating Patients With Recurrent Local
 ly Advanced or Metastatic Urothelial Cancer\nEstimated primary completion:
  30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03237780
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Atezolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies
  as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05112965)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: An Extension Study in Participa
 nts Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Spo
 nsored Atezolizumab Study (IMbrella C)\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 112965
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05595460-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05595460)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study 
 of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC\nEstimate
 d primary completion: July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05595460
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803994-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04803994)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: The 
 ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoemboli
 zation (TACE) in Intermediate-stage HepatoCellular Carcinoma\nEstimated pr
 imary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04803994
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04696575-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04696575)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Lamivu
 dine in Combination With Chemoimmunotherapy for the Treatment of Extensive
  Stage Small Cell Lung Cancer\nEstimated primary completion: 1 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04696575
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754501-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06754501)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Phase 2 Clinical Trial Evalua
 ting the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Ant
 i-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown P
 rimary\nEstimated primary completion: 1 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06754501
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05411081-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05411081)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Testing Cabozantinib With or Wi
 thout Atezolizumab in Patients With Advanced Papillary Kidney Cancer\, PAP
 MET2 Trial\nEstimated primary completion: 1 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05411081
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362252-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06362252)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of I-DXd in Combination With Atezolizumab With or Without Carboplatin 
 as First-Line Induction or Maintenance in Subjects With Extensive Stage-Sm
 all Cell Lung Cancer (IDeate-Lung03)\nEstimated primary completion: 20 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0636
 2252
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496568-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06496568)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Study Evaluating Single-agent
  Inavolisib\, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers\nEsti
 mated primary completion: 21 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06496568
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878691-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05878691)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Study of GRC 54276 in Partici
 pants With Advanced Solid Tumors and Lymphomas.\nEstimated primary complet
 ion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/at
 ezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05878691
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280377-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07280377)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study in Advanced or Metast
 atic Gastrointestinal Cancers Exploring Treatment Combinations With Pelare
 orep and Atezolizumab\nEstimated primary completion: 30 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07280377
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524871-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04524871)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Pa
 tients With Advanced Liver Cancers (Morpheus-Liver)\nEstimated primary com
 pletion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04524871
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06096779)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A St
 udy Evaluating Atezolizumab\, With or Without Bevacizumab\, in Participant
 s With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
 hosis\nEstimated primary completion: 30 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06096779
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04996017-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04996017)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: Atezolizumab Versus Placebo for
  the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)\nEst
 imated primary completion: 30 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04996017
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03181100-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03181100)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab With Chemotherapy 
 in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Canc
 er\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03181100
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03708224-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03708224)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Preoperative Immunotherapy in P
 atients With Squamous Cell Carcinoma of the Head and Neck\nEstimated prima
 ry completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03708224
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05423210-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05423210)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Atezolizumab and Pre-Surgical B
 rain Radiation Therapy for Glioblastoma Multiforme\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05423210
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695026-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06695026)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A 
 Study to Evaluate the Safety\, Tolerability and Efficacy of RZ-001 in Comb
 ination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subject
 s With Hepatocellular Carcinoma\nEstimated primary completion: August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06695026
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05001880-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05001880)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Chemotherapy With or Without Im
 munotherapy for Peritoneal Mesothelioma\nEstimated primary completion: 1 A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05001880
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059494-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Atezolizumab: Phase 4 readout est. (NCT07059494)
DESCRIPTION:Atezolizumab\, phase 4\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC
  for Liver Transplant\nEstimated primary completion: 1 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07059494
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649489-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04649489)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study to Evaluate Efficacy an
 d Safety of Hepatic Resection for Liver Cancer With PVTT\, HVTT or IVCTT A
 fter Initial Ate/Bev\nEstimated primary completion: 31 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04649489
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: The Drug Rediscovery Protocol (
 DRUP Trial)\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774247-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07774247)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab\, Bevacizumab\, and Tocilizumab in Advanced Hepatocellular Carcin
 oma\nEstimated primary completion: 1 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07774247
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pi
 lot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cel
 l Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated primary
  completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05085496-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05085496)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Radiotherapy in Combination Wit
 h Atezolizumab in Locally Advanced Borderline Resectable or Unresectable C
 utaneous SCC\nEstimated primary completion: 10 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05085496
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06444815-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06444815)
DESCRIPTION:Atezolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of VET3-TGI in Patients With Solid Tumors\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06444815
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03074513-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03074513)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab and Bevacizumab in
  Treating Patients With Rare Solid Tumors\nEstimated primary completion: 3
 0 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ate
 zolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03074513
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765084-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05765084)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Integration of the PD-L1 Inhi
 bitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based F
 irst-line Treatment for Epithelioid Malignant Pleural Mesothelioma\nEstima
 ted primary completion: October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05765084
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05312671-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05312671)
DESCRIPTION:Atezolizumab\, phase 2\, Bladder Cancer.\nStudy: Atezolizumab P
 lus Etoposide and Platinum in Small Cell Bladder Cancer\nEstimated primary
  completion: October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05312671
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05152472-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05152472)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Prospective\, Randomized\, Mu
 lticenter\, Comparative Study of the Efficacy of Imatinib Resumption Combi
 ned With Atezolizumab Versus Imatinib Resumption Alone in Patients With Un
 resectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure o
 f Standard Treatments\nEstimated primary completion: October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05152472
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04273061-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04273061)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Investigating the Effects of At
 ezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivit
 y\nEstimated primary completion: October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04273061
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907980-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05907980)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Phase I Study of ROSE12 Alone
  and in Combination With Other Anti-tumor Agents in Patients With Solid Tu
 mors\nEstimated primary completion: 31 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05907980
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03141684-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03141684)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Testing Atezolizumab Alone or A
 tezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sa
 rcoma\nEstimated primary completion: 31 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03141684
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332755-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06332755)
DESCRIPTION:Atezolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: St
 udy to Evaluate LB-LR1109\, Administered Alone for the Treatment of Solid 
 Tumor and in Combination With Atezolizumab for the Treatment of NSCLC\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06332755
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161532-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06161532)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Sacituzumab Govitecan With or W
 ithout Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Suc
 h as High Grade Neuroendocrine Carcinomas\, Adenocarcinoma\, and Squamous 
 Cell Bladder/Urinary Tract Cancer\, Renal Medullary Carcinoma and Penile C
 ...\nEstimated primary completion: 1 November 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06161532
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239245-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07239245)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizuma
 b Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinam
 o\nEstimated primary completion: 10 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07239245
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652686-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05652686)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expre
 ssing DLL3 (the SKYBRIDGE Study)\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0565268
 6
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05703971-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05703971)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Quar
 atusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-
 SCLC Patients\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05703971
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654400-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07654400)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-
 stage Small Cell Lung Cancer\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07654400
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y of RP2 in Combination With Second-line Therapy in Patients With Locally 
 Advanced or Metastatic HCC\nEstimated primary completion: 1 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Atezolizumab\, phase 2/3.\nStudy: Testing the Use of Investigat
 ional Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemo
 therapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cance
 rs\nEstimated primary completion: 15 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05063552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04919382-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04919382)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Temozo
 lomide and Atezolizumab for Subsequent Line for the Treatment of Metastati
 c or Recurrent Small Cell Lung Cancer\nEstimated primary completion: 30 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04919382
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06478693-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06478693)
DESCRIPTION:Atezolizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A St
 udy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancer
 s\, Including HCC\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06478693
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04449874-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT04449874)
DESCRIPTION:Atezolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Evaluate the Safety\, Pharmacokinetics\, and Activity of GDC-6036
  Alone or in Combination in Participants With Advanced or Metastatic Solid
  Tumors With a KRAS G12C Mutation\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044
 49874
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039281-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05039281)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Atezolizumab and Cabozantinib
  for the Treatment of Recurrent Glioblastoma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 tezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05039281
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Study of Precision Treatment fo
 r Rare Tumours in China Guided by PDO and NGS\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06692491
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05019703-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05019703)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab and Cabozantinib f
 or the Treatment of Adolescents and Young Adults With Recurrent or Metasta
 tic Osteosarcoma\, TACOS Study\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT050197
 03
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: TAPUR: Testing the Use of Food 
 and Drug Administration (FDA) Approved Drugs That Target a Specific Abnorm
 ality in a Tumor Gene in People With Advanced Stage Cancer\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202316-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03202316)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Atezolizumab\, Cobimetinib\, an
 d Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inf
 lammatory Breast Cancer\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03202316
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04981509-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04981509)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Testing of Bevacizumab\, Erloti
 nib\, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04981509
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Safety and Efficacy of HCB101
  in Combination With Multiple Agents in Patients With Advanced Solid Tumor
 s\nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06069726-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06069726)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Multicenter Trial to Identify
  Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma.
  The MOAB Trial\nEstimated primary completion: 1 January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06069726
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06003621-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06003621)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Tiragolumab and Atezolizumab in
  Advanced Pan-cancer Patients\nEstimated primary completion: 1 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06003621
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049848-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07049848)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: SATURN-STS: Phase II Study of N
 eoadjuvant Atezolizumab With Doxorubicin\, Concurrent Atezolizumab With Pr
 e-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With H
 igh-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma\n
 Estimated primary completion: 1 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07049848
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043674-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06043674)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Phase 2 Study of Glofitamab Mon
 otherapy & With Polatuzumab Vedotin\, Pirtobrutinib\, or Atezolizumab in R
 ichter's Transformation\nEstimated primary completion: 15 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06043674
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy in Participants With Advanced Cancers Associated With Expression of DL
 L3 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04471727
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06294548-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06294548)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A 
 Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizuma
 b in HCC\nEstimated primary completion: 30 January 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06294548
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05470595-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05470595)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Single-arm Trial of Atezolizu
 mab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendoc
 rine Cancer of the Lung\nEstimated primary completion: 31 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05470595
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02525757-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT02525757)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: MP
 DL3280A With Chemoradiation for Lung Cancer\nEstimated primary completion:
  31 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ate
 zolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02525757
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04727307-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04727307)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoa
 djuvant Atezo\, Adjuvant Atezo + Beva Combined With RF Ablation of Small H
 CC: a Multicenter Randomized Phase II Trial\nEstimated primary completion:
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezo
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04727307
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05542407-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05542407)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: ONC201 and Atezolizumab in Obes
 ity-Driven Endometrial Cancer\nEstimated primary completion: 21 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0554240
 7
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439485-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06439485)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Phase I/II Trial of Pemigatin
 ib in Combination With Atezolizumab and Bevacizumab for Treatment of Advan
 ced Cholangiocarcinoma With FGFR2 Fusion\nEstimated primary completion: 22
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezo
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06439485
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Study Evaluating the Efficacy
  and Safety of Biomarker-Driven Therapies in Patients With Persistent or R
 ecurrent Rare Epithelial Ovarian Tumors\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04931342
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031441-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06031441)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Study to Evaluate the Safety\
 , Pharmacokinetics\, and Activity of RO7566802 as a Single Agent and in Co
 mbination With Atezolizumab in Participants With Locally Advanced or Metas
 tatic Solid Tumors\nEstimated primary completion: 1 March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06031441
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142696-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280307
DTEND;VALUE=DATE:20280308
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05142696)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combinat
 ion With Carboplatin\, Etoposide and Atezolizumab\nEstimated primary compl
 etion: 7 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05142696
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528952-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05528952)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Eval
 uation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived
  From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatoc
 ellular Carcinoma\nEstimated primary completion: 27 March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05528952
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263438-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07263438)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Efficacy of the Combination of 
 Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent 
 Glioblastoma: a Phase 2 Trial\nEstimated primary completion: 30 March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07263438
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733038-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06733038)
DESCRIPTION:Atezolizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFOXIRI P
 lus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR
  and IS IC-High Metastatic Colorectal Cancer Patients.\nEstimated primary 
 completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06733038
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03175432-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03175432)
DESCRIPTION:Atezolizumab\, phase 2\, Melanoma.\nStudy: Bevacizumab and Atez
 olizumab With or Without Cobimetinib in Treating Patients With Untreated M
 elanoma Brain Metastases\nEstimated primary completion: 30 June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03175432
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012734-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06012734)
DESCRIPTION:Atezolizumab\, phase 1\, Colorectal Cancer.\nStudy: LB-100 (PP2
 A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal C
 ancer Patients\nEstimated primary completion: July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06012734
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Atezolizumab: Phase 4 readout est. (NCT06031233)
DESCRIPTION:Atezolizumab\, phase 4.\nStudy: Evaluating the Safety of Shorte
 ned Infusion Times for dIfferent Oncological Immunotherapie\nEstimated pri
 mary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06031233
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929051-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07929051)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study to Test Obrixtamig Trea
 tment in People With Different Types of Advanced Cancer Who Took Part in a
  Previous Study With Obrixtamig\nEstimated primary completion: 3 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07929051
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Patients Previously 
 Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezoliz
 umab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05581004-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05581004)
DESCRIPTION:Atezolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Evaluate the Safety\, Pharmacokinetics\, and Activity of Enzelkit
 ug as a Single Agent and in Combination With Checkpoint Inhibitor in Parti
 cipants With Locally Advanced or Metastatic Solid Tumors\nEstimated primar
 y completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05581004
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663098-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06663098)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Atezol
 izumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-st
 age Small Cell Lung Cancer (ES-SCLC).\nEstimated primary completion: 30 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6663098
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543510-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Atezolizumab: Phase na readout est. (NCT07543510)
DESCRIPTION:Atezolizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Low
 -Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable
  Hepatocellular Carcinoma\nEstimated primary completion: 31 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07543510
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472517-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280909
DTEND;VALUE=DATE:20280910
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07472517)
DESCRIPTION:Atezolizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: DAREON
  ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Com
 pare Obrixtamig Plus Atezolizumab\, Carboplatin\, and Etoposide Treatment 
 With Standard Chemoimmunotherapy\nEstimated primary completion: 9 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0747
 2517
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760481-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06760481)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: Phase I/Ib Trial of TIraGolumab
 \, AtEzolizumab\, and RadScopal Radiation in Patients With Advanced Solid 
 Malignancies (TIGER)\nEstimated primary completion: 15 September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06760481
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133062-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06133062)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatoc
 ellular Carcinoma\nEstimated primary completion: 30 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06133062
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03614949-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03614949)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: SBRT and Atezolizumab in the Ma
 nagement of Recurrent\, Persistent\, or Metastatic Cervical Cancer\nEstima
 ted primary completion: October 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03614949
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05058651-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05058651)
DESCRIPTION:Atezolizumab\, phase 2/3.\nStudy: Evaluating the Addition of th
 e Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for A
 dvanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the
  Lung\nEstimated primary completion: 1 October 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05058651
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Study of GSK5764227 in Partic
 ipants With Advanced Solid Tumors (EMBOLD)\nEstimated primary completion: 
 16 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atez
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06551142
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789757-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06789757)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: The 
 Study of Atezolizumab\, Bevacizumab and Memantine in Patients With Hepatoc
 ellular Carcinoma (HCC)\nEstimated primary completion: 27 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06789757
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407933-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07407933)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of YL201 in Combination With Other Anti-Cancer Therapies in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: November 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07407933
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681039-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05681039)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Phase 2 Trial of Neoadjuvant an
 d Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed 
 PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinom
 a (OCSCC).\nEstimated primary completion: 1 November 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05681039
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05334329-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05334329)
DESCRIPTION:Atezolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ge
 netically Engineered Natural Killer (NK) Cells With or Without Atezolizuma
 b for the Treatment of Non-small Cell Lung Cancer Previously Treated With 
 PD-1 and/or PD-L1 Immune Checkpoint Inhibitors\nEstimated primary completi
 on: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05334329
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170592-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT07170592)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Phase 1 Study of OTS-412 (Rec
 ombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Pat
 ients\nEstimated primary completion: December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07170592
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190833-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT07190833)
DESCRIPTION:Atezolizumab\, phase 1.\nStudy: A Phase 1 Study of OTS-412 (Rec
 ombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Pat
 ients (South Korea)\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07190833
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680258-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06680258)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A St
 udy of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unres
 ectable or Metastatic HCC Not Previously Treated With Systemic Therapy\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06680258
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317414-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07317414)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: β-a
 lanine in the Treatment of Advanced Hepatocellular Carcinoma\nEstimated pr
 imary completion: 5 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07317414
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05394337-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05394337)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Neoadjuvant PD-1 Plus TIGIT B
 lockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelia
 l Carcinoma\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05394337
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944237-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05944237)
DESCRIPTION:Atezolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: HTL003973
 2 in Participants With Advanced Solid Tumours\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05944237
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017455-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04017455)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Neoadjuvant Treatment in Rectal
  Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN
 )\nEstimated primary completion: 31 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04017455
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281664-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase na readout est. (NCT07281664)
DESCRIPTION:Atezolizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Tra
 nsarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab a
 s First-Line Treatment for Unresectable Hepatocellular Carcinoma\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07281664
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339059-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07339059)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study 
 of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Thera
 py for Extensive-Stage Small Cell Lung Cancer\nEstimated primary completio
 n: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 tezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07339059
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712643-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04712643)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A St
 udy of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in P
 atients With Untreated Heaptocellular Carcionma\nEstimated primary complet
 ion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04712643
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339424-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06339424)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatoc
 ellular Carcinoma\nEstimated primary completion: 30 March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06339424
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010497-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07010497)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pr
 ospective Study to Evaluate the Safety and Efficacy of the Combination The
 rapy of Irpagratinib\, Atezolizumab\, and Bevacizumab in Patients With Hep
 atocellular Carcinoma\nEstimated primary completion: 31 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07010497
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06823375-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06823375)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: SBRT With Immunotherapy and Ate
 zo-Bev in HCC With Major Portal Vein Thrombosis\nEstimated primary complet
 ion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 tezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06823375
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07155174)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Optimal Dose\, Adverse Events and Change in Disease Acti
 vity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Stand
 ard of Care as First-Line Treatment in Adult Participants With Previously 
 Untreated Extensive Stage Small Cell Lung Cancer\nEstimated primary comple
 tion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ate
 zolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07155174
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: ProTarget - A Danish Nationwide
  Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nE
 stimated primary completion: 30 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06632327)
DESCRIPTION:Atezolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Co
 mparing Impact of Treatment Before or After Surgery in Patients With Stage
  II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary completi
 on: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/at
 ezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06632327
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Treatment Combinations in Participants With Brea
 st Cancer\nEstimated primary completion: 30 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04802759
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461675-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07461675)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Effe
 cts of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular
  Carcinoma Patients Undergoing Liver Resection\nEstimated primary completi
 on: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atez
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07461675
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605664-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06605664)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Hype
 rpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Ra
 diotherapy\, Atezolizumab\, and Bevacizumab\nEstimated primary completion:
  30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06605664
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287775-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06287775)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Test
 ing the Combination of an Anti-cancer Drug\, Iadademstat\, With Other Anti
 -cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small
  Cell Lung Cancer\nEstimated primary completion: 25 July 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06287775
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QU
 ILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pre
 viously Received Treatment With Immune Checkpoint Inhibitors\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545954-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT07545954)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: DSP-03
 90 in Combination With Atezolizumab for Small Cell Lung Cancer\nEstimated 
 primary completion: 30 September 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07545954
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05770102-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05770102)
DESCRIPTION:Atezolizumab\, phase 2/3\, Colorectal Cancer.\nStudy: DETERMINE
  Trial Treatment Arm 02: Atezolizumab in Adult\, Paediatric and Teenage/Yo
 ung Adult Patients With Cancers With High Tumour Mutational Burden (TMB) o
 r Microsatellite Instability-high (MSI-high) or Proven Constitutional Mism
 atch Repair Deficiency (CMMRD) Disposition\nEstimated primary completion: 
 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05770102
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Atezolizumab\, phase 2/3.\nStudy: DETERMINE (Determining Extend
 ed Therapeutic Indications for Existing Drugs in Rare Molecularly Defined 
 Indications Using a National Evaluation Platform Trial) - Master Screening
  Protocol\nEstimated primary completion: October 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07835737-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07835737)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Sa
 fety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab
  as First-Line Therapy for Unresectable Hepatocellular Carcinoma\nEstimate
 d primary completion: 1 October 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07835737
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113691-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT07113691)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: Iadade
 mstat + SBRT With Atezo in ES-SCLC\nEstimated primary completion: January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071136
 91
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625644-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07625644)
DESCRIPTION:Atezolizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: BL-M14
 D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Sma
 ll Cell Lung Cancer (BrenDeLL-Lung01)\nEstimated primary completion: Janua
 ry 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 25644
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254248-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06254248)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Safe
 ty of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advance
 d Hepatocellular Carcinoma\nEstimated primary completion: 1 January 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06254248
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Genomics Guided Targeted Post-n
 eoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)\
 nEstimated primary completion: March 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286801-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05286801)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: Tiragolumab and Atezolizumab 
 for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient T
 umors\nEstimated primary completion: 31 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05286801
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707895-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07707895)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: DARE
 ON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People 
 With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEsti
 mated primary completion: 26 April 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07707895
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361395-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT05361395)
DESCRIPTION:Atezolizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: First-
 Line Tarlatamab in Combination With Carboplatin\, Etoposide\, and PD-L1 In
 hibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)\
 nEstimated primary completion: 30 May 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05361395
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929223-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Atezolizumab: Phase 1 readout est. (NCT04929223)
DESCRIPTION:Atezolizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study Eva
 luating the Safety and Efficacy of Targeted Therapies in Subpopulations of
  Patients With Metastatic Colorectal Cancer (INTRINSIC)\nEstimated primary
  completion: 31 August 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04929223
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03942328-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT03942328)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Mo
 dified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) C
 ombined With Immune Checkpoint Inhibition After High-Dose External Beam Ra
 diation Therapy in Treating Patients With Unresectable Liver Cancer\nEstim
 ated primary completion: 31 August 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03942328
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Treatment Combinations in Patients With Metastat
 ic or Locally Advanced Breast Cancer\nEstimated primary completion: 30 Sep
 tember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03424005
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322341-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07322341)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SX
 -682 and Atezolizumab for the Treatment of Advanced or Metastatic\, Recurr
 ent Non-small Cell Lung Cancer\nEstimated primary completion: 1 November 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0732234
 1
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Cl
 inical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) i
 n People With Small Cell Lung Cancer (MK-6070-003)\nEstimated primary comp
 letion: 29 November 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227597
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05968326-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05968326)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Study of the Efficacy and Saf
 ety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versu
 s mFOLFIRINOX Alone in Participants With Resected PDAC\nEstimated primary 
 completion: 1 January 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05968326
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947121-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310224
DTEND;VALUE=DATE:20310225
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07947121)
DESCRIPTION:Atezolizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Stud
 y of Risvutatug Rezetecan in Combination With Atezolizumab in Participants
  With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)\nEstimated 
 primary completion: 24 February 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07947121
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725121-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06725121)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Us
 ing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before T
 ransplant\nEstimated primary completion: June 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06725121
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018947-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07018947)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as N
 eoadjuvant Plus Adjuvant Treatment in HCC\nEstimated primary completion: J
 une 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 018947
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07895056)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity of Intravenous (
 IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Part
 icipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary co
 mpletion: August 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07895056
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05538091-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310830
DTEND;VALUE=DATE:20310831
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05538091)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Vismodegib Combined With Atezol
 izumab in Platinum Resistant Ovarian\, Fallopian Tube\, and Primary Perito
 neal Cancer\nEstimated primary completion: 30 August 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05538091
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: The Finnish National Study to F
 acilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary 
 completion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895043-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07895043)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity of Intravenous (
 IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Pa
 rticipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary 
 completion: December 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07895043
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468359-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05468359)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Sa
 fety and Efficacy of Cyclophosphamide\, Sorafenib\, Bevacizumab\, and Atez
 olizumab in Pediatric Solid Tumor Patients\nEstimated primary completion: 
 June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5468359
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Tumor-agnostic Precision Immuno
 -oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
 \nEstimated primary completion: 25 September 2032. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388524-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07388524)
DESCRIPTION:Atezolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Te
 sting the Impact of an Anti-Cancer Drug\, Atezolizumab\, After Surgery to 
 Prevent Early Stage Non-small Cell Lung Cancer From Returning\, AASI-NSCLC
  Trial\nEstimated primary completion: 30 September 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07388524
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Rollover Study for Participan
 ts Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored
  Study\nEstimated primary completion: 1 March 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153445-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20350502
DTEND;VALUE=DATE:20350503
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07153445)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for 
 the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)\nEstimated p
 rimary completion: 2 May 2035. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07153445
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Co
 ncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiati
 on Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary com
 pletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817956-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20400330
DTEND;VALUE=DATE:20400331
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04817956)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Improving Public Cancer Care by
  Implementing Precision Medicine in Norway\nEstimated primary completion: 
 30 March 2040. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04817956
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05620771-1962@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20400701
DTEND;VALUE=DATE:20400702
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05620771)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ther
 asphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma 
 That is High-risk\nEstimated primary completion: 1 July 2040. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05620771
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
